Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

Why is Kraft Heinz removing artificial dyes by 2027? How will Senate tax bill affect renewable energy stocks? What caused JetBlue to cut flights amid weak demand? Why did JPMorgan raise its Sapphire Reserve card fee? How is Trump’s Iran stance impacting oil prices? What’s behind Meta adding ads to WhatsApp now? Why is OpenAI’s partnership with Microsoft strained?

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

benzinga.com/news/health-care/25/06/45973605/mineralys-therapeutics-investigational-drug-shows-benefit-in-hypertensive-patients-with-chronic-

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) revealed topline data Tuesday from its Phase 2 Explore-CKD trial, which evaluated the safety and efficacy of 25 mg of lorundrostat in subjects with hypertension and comorbid CKD.
The crossover trial met the primary endpoint and demonstrated…

This story appeared on benzinga.com, 2025-06-17 13:57:25.